Ministerial Ordinance on Good Clinical Practice for Drugs: Pharmaceuticals and Medical Devices Agency, Japan
The following English translations of Japanese ministerial ordnances are intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese originals and the translations, the former shall prevail. Provisional Translation (as of March 2013)∗
'Ministerial Ordinance on Good Clinical Practice for Drugs (as amended, effective December 28, 2012)', source: Pharmaceuticals and Medical Devices Agency, Japan.
Ministerial Ordinance on Good Clinical Practice for Drugs
Ordinance of the Ministry of Health and Welfare No. 28 of March 27, 1997
(As last amended by the Ordinance of Ministry of Health, Labour and Welfare No. 161 of December 28, 2012)
The Ministerial Ordinance on Good Clinical Practice (GCP) for Drugs shall be established as stated below in accordance with the following provisions of the Pharmaceutical Affairs Act (Act No. 145 of 1960): Article 14, Paragraph 3 (including cases where it shall apply mutatis mutandis in Article 14, Paragraph 6; Article 19-2, Paragraph 4; and Article 23 of the same Act),
Article 14-4, Paragraph 4, and Article 14-5, Paragraph 4 (including cases where these provisions shall apply mutatis mutandis in Article 19-4 and Article 23 of the same Act); Article 80-2, Paragraphs 1, 4 and 5; and Article 82.
Table of Contents
-
Chapter I. General Provisions (Articles 1 through 3)
-
Chapter II. Standards for Preparing Clinical Trials
-
Chapter III. Standards for Clinical Trial Management
-
Chapter IV. Standards for Conducting Clinical Trials
-
Chapter V. Standards for Documents Submitted in Reexamination etc. (Article 56)
-
Chapter VI. Standards for Sponsoring Clinical Trials etc. (Articles 57 through 59)
-
Supplementary Provisions
Disclamer: We take possible measures to ensure the accuracy of information published on this website, however, GCP Network will not assume any responsibility for any decisions/activities/actions which the user of our site performed by using any information published here.
Clinical Research News
Upcoming Clinical Research Events
-
08 – 11 October 2023
TransCelerate BioPharma
United States -
08 – 11 October 2023
SCDM (Society of Clinical Data Management)
United States -
16 – 17 October 2023
The Conference Forum
United States -
17 – 18 October 2023
Cambridge Innovation Institute
Spain -
01 – 03 November 2023
RQA (Research Quality Association)
United Kingdom -
11 – 15 November 2023
AMIA (American Medical Informatics Association)
United States -
15 – 16 November 2023
World BI
United States -
29 – 30 November 2023
Informa
Spain
Připravované klinické studie
-
NCT06067425Zatím nenabíráme
-
NCT06066489Zatím nenabíráme
-
NCT06067165Zatím nenabírámeProblém duševního zdraví
-
NCT06066242Zatím nenabíráme
-
NCT06066021Zatím nenabírámeRetinopatie, diabetici
-
NCT06066138Zatím nenabírámeMetastatický melanom | Lokálně pokročilý melanom | Metastatický alveolární sarkom měkkých částí | Metastatický nemalobuněčný karcinom plic | Metastatický hepatocelulární karcinom | Lokálně pokročilý hepatocelulární karcinom | Metastatický malobuněčný karcinom plic | Lokálně pokročilý nemalobuněčný karcinom plic | Lokálně pokročilý alveolární sarkom měkkých částí | Lokálně pokročilý malobuněčný karcinom plic
-
NCT06065930NáborObezita | Cukrovka typu 2
-
NCT06066112NáborSchizofrenie | Bioekvivalence
-
NCT06066866Zatím nenabírámeZdravý | Zánětlivá onemocnění střev | IBS – Syndrom dráždivého tračníku